NCT02953782 is a Phase 1, PHASE2 clinical trial of Magrolimab in Solid Tumor, sponsored by Gilead Sciences.

Who is sponsoring NCT02953782?

NCT02953782 is sponsored by Gilead Sciences.

What drugs are being tested in NCT02953782?

Interventions in NCT02953782: Magrolimab, Cetuximab.

What condition does NCT02953782 study?

NCT02953782 studies Solid Tumor, Colorectal Cancer.

Is NCT02953782 still recruiting?

NCT02953782 is currently completed. Last updated 1 March 2021.

Are results published for NCT02953782?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-01 · How we verify

NCT02953782

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Completed Phase 1, PHASE2 Results posted Last updated 1 March 2021

What this trial tests

Phase 1, PHASE2 trial testing Magrolimab in Solid Tumor in 78 participants. Completed in 10 February 2020.

Timeline

2 November 2016

Primary endpoint
10 February 2020

10 February 2020

Quick facts

Lead sponsor	Gilead Sciences
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	2 November 2016
Primary completion	10 February 2020
Estimated completion	10 February 2020
Sites	8 locations across United States

Drugs / interventions tested

Magrolimab — full drug profile →
Cetuximab (cetuximab) — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Gilead Sciences — full company profile →

Who can join

18 and older, any sex, with Solid Tumor or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants With Dose Limiting Toxicities (DLT) Primary · From first dose up to Day 28

DLT was defined as any Grade (GR) 3 or greater adverse event (AE) that was assessed as related to study treatment with the exceptions of: GR 3: anemia (hemolytic anemia that is medically significant tis considered a DLT), indirect/unconjugated hyperbilirubinemia, electrolyte abnormalities, elevation in alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase that resolved to ≤ Grade 2 with supportive care within 1 week and is not associated with other clinically significant consequences; nausea, vomiting, or diarrhea that resolved to ≤ Grade 2 with supportive care within

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	16.7
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.0
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.0
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	14.3
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.0
Phase 2 Cohort 1 Safety Run-in: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.0

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Primary · From first dose date up to last dose date plus 30 days (maximum: 15.3 months)

An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as AEs worsening or occurring during or after a participant's first exposure to study drug and within 30 days after the last administration of study drug or initiation of new anticancer therapy, whichever occurred first.

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	100.0
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	100.0
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	100.0
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	100.0
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	100.0
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	100.0
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	100.0
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	100.0
Magrolimab Priming Dose Only	100.0

Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Primary · From Screening until 38.89 months (assessed on Day 1 of Cycle 3 then every 8 weeks [Q8W] from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

Objective response rate was defined as the percentage of participants with objective response which consisted of complete response (CR)+ partial response (PR) determined by RECIST v 1.1. CR: Disappearance of all target and all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\< 10 mm short axis). Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Group	Value	95% CI
KRASwt CRC	6.3	0.8 – 20.8
KRASm CRC	0.0	0.0 – 8.4

Pharmacokinetic (PK) Parameter: Cmax of Magrolimab Secondary · Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 1 (Cycle 1 Day 1), 8 (Cycle 1 Day 8), and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

Cmax is defined as the maximum concentration of drug.

Day 1 (Cycle 1 Day 1)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	1.04	± 0.769
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.629	± 0.437
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.662	± 0.374
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.432	± 0.173
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.517	± 0.311
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.479	± 0.170
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.559	± 0.254
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.525	± 0.296

Day 8 (Cycle 1 Day 8)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	209	± 82.0
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	230	± 54.6
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	455	± 105
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	558	± 168
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	1100	± 287
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	513	± 148
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	616	± 121
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	901	± 131

Day 29 (Cycle 2 Day 1)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	312	± 121
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	352	± 68.4
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	728	± 207
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	982	± 182
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	2140	± 590
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	775	± 110
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	1790	± 49.5

PK Parameter: Tmax of Magrolimab Secondary · Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 8 (Cycle 1 Day 8) and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

Tmax is defined as the time (observed time point) of Cmax.

Day 8 (Cycle 1 Day 8)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	0.10	0.09 – 0.12
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.12	0.09 – 0.13
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.12	0.12 – 6.94
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.14	0.12 – 0.85
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.13	0.12 – 3.90
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.12	0.08 – 6.82
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.13	0.12 – 0.17
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.12	0.11 – 6.99

Day 29 (Cycle 2 Day 1)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	0.94	0.10 – 1.09
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.13	0.12 – 0.13
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.13	0.12 – 0.96
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.13	0.10 – 0.15
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.12	0.12 – 0.13
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.14	0.14 – 0.14
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.12	0.12 – 0.12

PK Parameter: AUClast of Magrolimab Secondary · Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 8 (Cycle 1 Day 8) and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Day 8 (Cycle 1 Day 8)

Group	Value	95% CI
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	676	± 75.3
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	1530	± 513
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	2140	± 726
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	2920	± 600
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	1930

Day 29 (Cycle 2 Day 1)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	1420	± 711
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	1560	± 413
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	3330	± 1270
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	4480	± 1220
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	7340	± 2380

PK Parameter: AUCtau of Magrolimab Secondary · Pre-magrolimab dose (within 12 hours) and 1-hour post-magrolimab dose (infusion duration = approximately 3 hours on Day 1 and 2 hours on other days) on Days 8 (Cycle 1 Day 8) and 29 (Cycle 2 Day 1) (1 cycle = 4 weeks)

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Day 8 (Cycle 1 Day 8)

Group	Value	95% CI
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	676	± 75.3
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	1630	± 649
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	2140	± 726
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	1930

Day 29 (Cycle 2 Day 1)

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	1640	± 604
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	1560	± 413
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	3630	± 1040
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	4480	± 1220
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	8770	± 1120

Percentage of Participants With Anti-drug Antibodies (ADA) Secondary · Baseline; post-treatment (assessed continuously up to 30 days after last dose; maximum 15.3 months )

Percentage of Participants With Positive ADA at any timepoint was reported.

Baseline ADA

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	0.00
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	14.3
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	6.3
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.00

Post-Treatment ADA

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	33.3
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	6.3
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	13.3
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.00

Overall ADA

Group	Value	95% CI
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2	33.3
Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	14.3
Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.00
Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	12.5
Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2	13.3
Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2	0.00

Disease Control Rate (DCR) as Assessed by RECIST v1.1 Secondary · From Screening until 38.89 months (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

DCR was defined as the percentage of participants with disease control which consisted of CR+PR+SD. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters measured while on study. PD: At least a 20% increase in the sum of diamete

Group	Value	95% CI
KRASwt CRC	50.0	31.9 – 68.1
KRASm CRC	38.1	23.6 – 54.4

Duration of Response (DOR) as Assessed by RECIST v1.1 Secondary · From first objective response until documented PD (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

DOR was measured from when the first (objective) response was met (i.e., CR or PR) until the first date of objectively documented PD. Participants who did not have objectively PD was censored at their last documented progression-free date. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the sm

Group	Value	95% CI
KRASwt CRC	9.7	7.0 – 12.5

Progression Free Survival (PFS) as Assessed by RECIST v1.1 Secondary · From first dose until documented PD/death (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

PFS was measured from first dose until the first date of objectively documented PD or death. Participants who did not have objectively documented PD and not died was censored at their last documented progression-free date. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Kaplan

Group	Value	95% CI
KRASwt CRC	3.6	1.8 – 5.4
KRASm CRC	1.9	1.8 – 3.5

Overall Survival (OS) Secondary · From first dose until death (assessed on Cycle 3 Day 1 then every 8 weeks from Cycle 5 onwards up to 38.89 months; 1 cycle = 4 weeks)

OS was measured from first dose until death. Participants who did not die were censored at their last known alive date. Kaplan Meier estimate was used for analysis.

Group	Value	95% CI
KRASwt CRC	9.5	5.9 – 12.6
KRASm CRC	7.6	5.4 – 11.7

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse Events: From first dose date up to last dose date plus 30 days (maximum: 15.3 months); All-Cause mortality: From first dose date up to 38.89 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Magrolimab 10 mg/kg

Serious: 3/9 (33%)

Deaths: 7/9

Magrolimab 20 mg/kg

Serious: 6/10 (60%)

Deaths: 8/10

Magrolimab 30 mg/kg

Serious: 10/36 (28%)

Deaths: 30/36

Magrolimab 45 mg/kg

Serious: 5/20 (25%)

Deaths: 14/20

Magrolimab Priming Dose Only

Serious: 1/3 (33%)

Deaths: 3/3

Serious adverse events (28 terms)

Reaction	System	Magrolimab 10 mg/kg	Magrolimab 20 mg/kg	Magrolimab 30 mg/kg	Magrolimab 45 mg/kg	Magrolimab Priming Dose Only
Malignant neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Immune thrombocytopenic purpura	Blood and lymphatic system disorders	—	—	—	—	—
Bradycardia	Cardiac disorders	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—
Enterocolitis	Gastrointestinal disorders	—	—	—	—	—
Faecaloma	Gastrointestinal disorders	—	—	—	—	—
Large intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—
Complication associated with device	General disorders	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—
Bacterial sepsis	Infections and infestations	—	—	—	—	—
Cystitis	Infections and infestations	—	—	—	—	—
Post procedural infection	Infections and infestations	—	—	—	—	—
Bilirubin conjugated increased	Investigations	—	—	—	—	—
International normalised ratio increased	Investigations	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—
Hyperkalaemia	Metabolism and nutrition disorders	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—
Pathological fracture	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Cerebrovascular accident	Nervous system disorders	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—

Other adverse events (157 terms — click to expand)

Reaction	System	Magrolimab 10 mg/kg	Magrolimab 20 mg/kg	Magrolimab 30 mg/kg	Magrolimab 45 mg/kg	Magrolimab Priming Dose Only
Fatigue	General disorders	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—
Dermatitis acneiform	Skin and subcutaneous tissue disorders	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—
Chills	General disorders	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—
Dry skin	Skin and subcutaneous tissue disorders	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—	—
Rash pruritic	Skin and subcutaneous tissue disorders	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—
Vitreous floaters	Eye disorders	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—
Pain	General disorders	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—

Most-reported serious reactions: Malignant neoplasm progression, Small intestinal obstruction, Urinary tract infection, Infusion related reaction, Anaemia, Immune thrombocytopenic purpura, Bradycardia, Constipation.

Data from ClinicalTrials.gov NCT02953782 adverse events section.

Sponsor's own description

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor microenvironment as a therapeutic target in cancer.
Xiao Y, Yu D. · · 2021 · cited 1438× · PMID 33259885 · DOI 10.1016/j.pharmthera.2020.107753
Macrophages as tools and targets in cancer therapy.
Mantovani A, Allavena P, Marchesi F, Garlanda C. · · 2022 · cited 1279× · PMID 35974096 · DOI 10.1038/s41573-022-00520-5
Phagocytosis checkpoints as new targets for cancer immunotherapy.
Feng M, Jiang W, Kim BYS, Zhang CC, et al · · 2019 · cited 729× · PMID 31462760 · DOI 10.1038/s41568-019-0183-z
Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
Ngambenjawong C, Gustafson HH, Pun SH. · · 2017 · cited 659× · PMID 28449873 · DOI 10.1016/j.addr.2017.04.010
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic BI, Lakhani N, Patnaik A, Shah SA, et al · · 2019 · cited 484× · PMID 30811285 · DOI 10.1200/jco.18.02018
Targeting macrophages in cancer immunotherapy.
Duan Z, Luo Y. · · 2021 · cited 462× · PMID 33767177 · DOI 10.1038/s41392-021-00506-6
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038
Drugging the efferocytosis process: concepts and opportunities.
Mehrotra P, Ravichandran KS. · · 2022 · cited 319× · PMID 35650427 · DOI 10.1038/s41573-022-00470-y

Verify or expand the search:

Other trials of Magrolimab

Trials testing the same drug.

NCT05367401 — A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants · Phase 1, PHASE2 · withdrawn
NCT05823480 — Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS · Phase 1 · withdrawn
NCT05829434 — Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS · Phase 2 · withdrawn
NCT05807126 — Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of · Phase 1 · withdrawn
NCT06046482 — Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous C · Phase 2 · terminated

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Gilead Sciences trials

Trials by the same sponsor.

NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02953782 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 1 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02953782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02953782

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (28 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Magrolimab

Other recruiting trials for Solid Tumor

Other Gilead Sciences trials

Verify against primary sources